Point of care (PoC) diagnostics refers to medical tests that can be performed quickly and easily at or near the site of patient care, such as a hospital or doctor’s office. Point-of-care diagnostics products quickly determine a marker responsible for a certain disease. These tests can be used in various point-of-care settings such as physician offices, urgent care facilities, long-term care facilities, and nursing homes.
Point-of-Care Diagnostics Market is Projected to Reach $43.1 billion by 2030, at a CAGR of 5.1% During the forecast period, Says Meticulous Research®
Here are the Top 10 Companies Operating in the Point-of-care Diagnostics Market
Abbott Laboratories (U.S.)
Incorporated in 1888 and headquartered in Illinois, U.S., Abbott Laboratories develops, manufactures, and markets a diverse range of healthcare products. The company operates through four reportable business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The Diagnostic Products segment operates in the point-of-care diagnostics market. This segment comprises core laboratory and transfusion medicine systems, molecular diagnostics polymerase chain reaction (PCR) instrument systems, point of care systems, rapid diagnostics lateral flow testing products, and informatics and automation solutions.
Furthermore, the Diagnostic Products segment offers a broad line of diagnostic systems and tests manufactured, marketed, and sold to blood banks, hospitals, commercial laboratories, clinics, physicians’ offices, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic firms globally.
Abbott is present across various countries like Germany, Japan, India, Switzerland, Russia, France, Brazil, Italy, the U.K., the U.S., the Netherlands, Colombia, and Vietnam. The company operates through its 88 manufacturing facilities globally, of which 22 are for diagnostic product manufacturing. The company has R&D centers in various countries, including Colombia, India, Singapore, Spain, and the U.K.
F. Hoffman-La Roche Ltd (Switzerland)
Founded in 1896 and established in Basel, Switzerland, Roche is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable business divisions, namely, Pharmaceuticals and Diagnostics.
The Diagnostics division operates in the point-of-care diagnostics market. This division develops a wide range of diagnostic products and solutions, including in vitro diagnostics, molecular diagnostics, clinical chemistry & immunoassays, point-of-care testing, tissue diagnostics, patient self-testing, and next-generation sequencing laboratory automation and IT, and decision support solutions.
Roche has a strong presence across the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Brazil, Mexico, and South Africa. It also has subsidiaries across the globe to fulfill its production and sales needs.
Siemens Healthineers AG (Germany)
Founded in 1847 and headquartered in Erlangen, Germany, Siemens Healthineers AG provides healthcare solutions and services. The company operates in four different segments, namely, Imaging, Diagnostics, Varian, and Advanced Therapies. The Diagnostics segment operates in the point-of-care diagnostics market. This segment comprises in-vitro diagnostic products and services for laboratory, molecular and point-of-care diagnostics.
The company has a direct presence in over 70 countries, with main manufacturing sites in the U.S., China, and Germany. The company produces, develops, and sells various therapeutic and diagnostic services and products to healthcare providers in over 180 countries.
Danaher Corporation (U.S.)
Founded in 1969 and headquartered in Washington DC, U.S., Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through four reportable business segments, namely, Biotechnology, Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Diagnostics segment offers point-of-care solutions.
The Diagnostics business segment offers a wide range of analytical instruments, reagents, consumables, software, and services to diagnose disease and make crucial treatment decisions and serves hospitals, physicians’ offices, reference laboratories, and other critical care settings. Among all its subsidiaries, Cepheid (U.S.), HemoCue AB (Sweden), and Radiometer Medical ApS (Denmark) are the subsidiaries of the company providing point-of-care diagnostics products.
The company has a presence in over 60 countries. Besides the U.S., the company has a significant presence in China, Denmark, Germany, Singapore, Sweden, Switzerland, and the U.K. Further, manufacturing facilities of the Diagnostics segment are located in North America, Europe, Asia, and Australia.
Thermo Fisher Scientific Inc. (U.S.)
Founded in 2006 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific offers various healthcare technologies, software, and services. The company operates through four reportable business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
The company operates in the point-of-care diagnostics market through its Life Sciences Solutions and Specialty Diagnostics business segments. The Life Sciences Solutions business segment offers a wide range of reagents, instruments, and consumables used in biological and medical research, the discovery and production of new drugs and vaccines, and the diagnosis of infection and disease. The Specialty Diagnostics business segment offers various diagnostic test kits, reagents, instruments, culture media, and associated products used in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.
Thermo Fisher has operations and a presence in approximately 50 countries outside the U.S. The company has major manufacturing and distribution facilities worldwide, including in the U.S., Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, and the U.K.
Meticulous Research in its latest publication on Point Of Care Diagnostics Market has predicted the growth of 5.1% during the forecast year 2023-2030
Becton, Dickinson and Company (U.S.)
Founded in 1897 and headquartered in New Jersey, U.S., Becton, Dickinson and Company is a medical technology firm engaged in developing, manufacturing, and selling a broad line of medical d evices, supplies, laboratory equipment, and diagnostic products. The company offers its products to healthcare institutions, life science researchers, physicians, clinics, diagnostic laboratories, and the pharmaceutical industry.
BD operates through three reportable business segments, namely, BD Medical, BD Life Sciences, and BD Interventional. The BD Life Sciences segment offers products for the safe collection and transportation of diagnostic specimens and instruments and reagent systems to detect various infectious diseases, healthcare-associated infections, and cancers. The BD Life Sciences segment comprises two organizational units: Integrated Diagnostic Solutions and Biosciences. The company operates in the point-of-care diagnostics market through Integrated Diagnostic Solutions, an organizational unit of the BD Life Sciences business segment.
The company has manufacturing facilities outside the U.S. in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain, and the U.K.
bioMérieux S.A (France)
Founded in 1963 and headquartered in Marcy-l’Étoile, France, bioMérieux develops, manufactures, and markets in vitro diagnostic solutions. The company operates in two main segments, Clinical Applications and Industrial Applications. The Clinical Applications segment operates in the point-of-care diagnostics market and provides diagnostic solutions that help doctors and healthcare workers determine the source of diseases. This segment is further categorized into microbiology, immunoassays, and molecular biology.
The company also has a presence in nearly 45 countries, including India, Japan, South Korea, the U.S., Mexico, Canada, Brazil, Colombia, Argentina, Thailand, Singapore, Austria, Denmark, Germany, the U.K., and Australia. Furthermore, it provides services with a huge network of suppliers in over 160 countries worldwide.
QuidelOrtho Corporation (U.S.)
Founded in 1979 and headquartered in California, U.S., QuidelOrtho Corporation develops and manufactures diagnostic solutions. The company operates through four business segments: Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. It operates in the point-of-care market through the Point of Care segment. This segment consists of instruments and tests which provide rapid results. These tests can be performed by professional healthcare providers or in a home-care setting. Further, these tests also run on portable POC analyzers.
The company directly sells its products to end users through a direct sales force channel and a network of distributors. The company has a global presence in more than 130 countries, with manufacturing facilities in the U.S. and U.K. As of January 2023, the company had approximately 7,000 employees, among which approximately 4,200 employees are located in the U.S. and approximately 2,800 outside the U.S.
The company has primary distribution centers in North America and Europe.
Sekisui Diagnostics, LLC. (a part of SEKISUI Chemical Co. Ltd.) (U.S.)
Founded in 1981 and headquartered in Massachusetts, U.S., Sekisui Diagnostics is involved in developing and innovating reagents, highly accurate diagnostics tests, and systems. The company is associated with the SEKISUI Chemical Co. Ltd. family, and SEKISUI Medical is its sister company. Sekisui Diagnostics provides a range of molecular point-of-care, rapid tests with high quality and fast immunoassay systems.
Sekisui Diagnostics has over 550 employees worldwide, with manufacturing and R&D facilities. The company offers various applications with high-quality materials, including point-of-care testing immunoassay or biosensor devices, coagulation reagents, clinical chemistry reagents, enzymes, specialty biochemicals for biotherapeutic manufacture, rapid tests, and preanalytic systems.
Some of its subsidiaries are SEKISUI Medical Co., Ltd (Japan), SEKISUI Diagnostics Limited (U.K.), SEKISUI Diagnostics P.E.I. Inc. (Canada), SEKISUI Diagnostics GmbH (Germany), and SEKISUI Medical Technology Ltd. (China).
Founded in 1966 and headquartered in Barcelona, Spain, Werfen develops, manufactures and distributes specialized diagnostic instruments, related reagents, automation work cells, and data management solutions. The company operates under three segments: Acute Care Diagnostics, Hemostasis, and Autoimmunity. Werfen is also an Original Equipment Manufacturing (OEM) company that researches, develops and produces tailored biomaterials and assays. Its OEM technology center is located in Barcelona, Spain.
With technology centers in Germany and the U.S., the company sells its products in nearly 30 countries and operates in over 100 territories through distributors
Popular Mentions: CHEMBIO DIAGNOSTICS, INC. (A subsidiary of Biosynex) (U.S.), EKF Diagnostics Holdings plc(U.K.), Trinity Biotech plc (Ireland), and Nova biomedical (U.S.)
Authoritative Research on the Point Of Care Diagnostics Market – Global Opportunity Analysis and Industry Forecast (2023-2030)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more: https://www.meticulousresearch.com/download-sample-report/cp_id=4871